Post Authorisation Safety Registry for US Patients With Generalised Lipodystrophy Treated With Metreleptin
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2016 |
| End Date: | October 2029 |
| Contact: | AstraZeneca Clinical Study Information Center |
| Email: | information.center@astrazeneca.com |
| Phone: | 1-877-240-9479 |
Metreleptin Safety Registry
Post Authorisation Safety Registry for US patients with Generalised Lipodystrophy treated
with Metreleptin
with Metreleptin
Post Authorisation Safety Registry for US patients with Generalised Lipodystrophy treated
with Metreleptin.
This registry will add to the knowledge about metreleptin gained from clinical trials by
providing information on the incidence rates of acute pancreatitis, hypoglycemia,
hypersensitivity and lymphoma in patients treated with metreleptin in routine clinical
practice.
with Metreleptin.
This registry will add to the knowledge about metreleptin gained from clinical trials by
providing information on the incidence rates of acute pancreatitis, hypoglycemia,
hypersensitivity and lymphoma in patients treated with metreleptin in routine clinical
practice.
Inclusion Criteria:
- Patients who are treated with metreleptin as part of clinical care
- Patients who provide a written consent
Exclusion Criteria:
- Patient receiving metreleptin as part of a clinical trial or through expended access
including compassionate use
- Patients currently treated with an investigational agent as part of a clinical trial
We found this trial at
1
site
Click here to add this to my saved trials
